
Research Square (Research Square), Год журнала: 2024, Номер unknown
Опубликована: Авг. 19, 2024
Язык: Английский
Research Square (Research Square), Год журнала: 2024, Номер unknown
Опубликована: Авг. 19, 2024
Язык: Английский
bioRxiv (Cold Spring Harbor Laboratory), Год журнала: 2024, Номер unknown
Опубликована: Авг. 8, 2024
Abstract Alzheimer’s disease (AD) is the major cause of senile dementia without effective therapeutic strategies. The fundamental role microglia in AD pathology, particularly early stages, well acknowledged, although cell-specific targets were not identified. Here we show that microglial connexin 43 (Cx43) hemichannels controls reactivity AD, thus being a promising target. We discovered marked increase Cx43 protein periplaque post-mortem tissue from patients. Subsequently, using APP swe /PS1 dE9 mouse model demonstrated operating as influences function, which turn affects β-amyloid pathology. Ablation by genetic knockout shifted to neuroprotective phenotype, promoted microglia-plaque interaction while suppressing neurotoxic signature, thereby mitigating progression AD. Following this lead, developed novel formulation small molecule peptide, lipid nanoparticle-delivered TAT-Cx43 266-283 (TAT-CX43@LNPs), selectively blocks hemichannels. Our preclinical trial its efficacy delaying and rescuing β-amyloid-related neuropathology cognitive impairment mice. This study provides strong evidence progress our drug into clinical trials translate it disease-preventing (when administered stages) disease-modifying agents.
Язык: Английский
Процитировано
0Research Square (Research Square), Год журнала: 2024, Номер unknown
Опубликована: Авг. 19, 2024
Язык: Английский
Процитировано
0